This report provides an analytical snapshot of the current state of the vaccine industry, its development efforts, and an outlook to 2020, examining:
•Vaccines for prevention of infectious diseases including hepatitis, influenza, polio, rabies, tropical viruses, and HIV
•Therapeutic vaccines that target HIV, HCV, asthma and allergy, type 1 diabetes, multiple sclerosis, psoriasis, arthritis, atherosclerosis, transplant rejection, Alzheimer’s disease, periodontitis, substance abuse, obesity, cachexia, and age-related macular degeneration
•Therapeutic cancer vaccines, including all cancer vaccines currently known to be in Phase III clinical trials and an overview of products that are in Phase I or II
•Perspectives for vaccine development, the direction the markets are likely to take to 2020, and estimates for market growth
•Results of a four-part survey offering unique insights into industry sentiment concerning vaccine development to 2020
•Advances in vaccine design, formulation, and delivery
•Company profiles of large pharmaceutical players in the vaccine business and small vaccine specialist companies
New Trends in Preventive and Therapeutic Vaccines: R&D Activities and Commercial Prospects begins by dealing with the major task of vaccines: prevention of infectious diseases. A thorough overview of vaccine-preventable diseases is given, with a special focus on human immunodeficiency virus (HIV), hepatitis C, and influenza. We use the case of a potential HIV vaccine for an analysis of how the first vaccine for a previously “unvaccinable”
We then turn to therapeutic vaccines that target chronic infectious diseases, but also non-infectious conditions with massive immune system involvement. A special section addresses efforts to develop therapeutic vaccines for conditions that most people would not consider targets for this type of intervention. Therapeutic cancer vaccines are covered in a separate chapter. This part of the report reviews the paradigms of active immune intervention in cancer and the problems it faces, as well as discusses cancer vaccines in clinical development. Standardized cancer vaccines, which work by harnessing the patient’s immune system, should offer a completely new therapeutic angle. Most importantly, they would be best suited to prevent tumor recurrence once a complete remission has been achieved by initial therapy—which would open an entirely new perspective for cancer survivors, and a completely new market as well.
Insight Pharma Reports conducted a four-part online survey in late September/early October 2011, which covered preventive vaccines for infectious diseases in general, influenza vaccines, HIV and HCV vaccines, and cancer vaccines. Analyses of the responses can be found throughout this report.
For more information and to purchase this Insight Pharma Report, visit: http://www.InsightPharmaReports.com
About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.InsightPharmaReports.com
# # #
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.